Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry

Archive ouverte

Bhandari, Sanjeeb | Gabrielle, Pierre-Henry | Nguyen, Vuong | Daien, Vincent | Viola, Francesco | Bougamha, Walid | Young, Stephanie | Romero-Nuñez, Barbara | Figueras-Roca, Marc | Zarranz-Ventura, Javier | Barthelmes, Daniel | Sararols, Laura | Gillies, Mark | Creuzot-Garcher, Catherine

Edité par CCSD ; Springer Verlag -

International audience. Introduction: Phase III clinical trials of dexamethasone intravitreal implant for diabetic macular oedema (DMO) have reported significant improvements in visual acuity (VA). Studies evaluating the treatment of DMO in routine clinical practice provide data to identify areas that need improvement. This study evaluated 12-month treatment outcomes of dexamethasone implant for DMO in routine clinical practice. Methods: Retrospective data analysis of eyes that started dexamethasone implant for DMO from 1 June 2013 to 30 April 2019 in routine clinical practice tracked in the Fight Retinal Blindness! Registry.

Suggestions

Du même auteur

Three-Year Treatment Outcomes of Aflibercept Versus Ranibizumab for Diabetic Macular Edema: Data from the Fight Retinal Blindness! Registry

Archive ouverte | Gabrielle, Pierre-Henry | CCSD

International audience. PURPOSE: Compare the three-year outcomes of ranibizumab versus aflibercept in eyes with DME in daily practice. METHODS: This was a retrospective analysis of naive DME eyes starting intravitre...

Ranibizumab or aflibercept for diabetic macular edema: Comparison of 1-year outcomes from the fight retinal blindness! Registry

Archive ouverte | Bhandari, Sanjeeb | CCSD

Supplemental material available at www.aaojournal.org.. International audience. PURPOSE: Both ranibizumab and aflibercept improved vision and decreased macular thickness in eyes with diabetic macular edema (DME) in ...

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis

Archive ouverte | Gabrielle, Pierre-Henry | CCSD

International audience. PURPOSE: To report the 36-month treatment outcomes of eyes with neovascular age-related macular degeneration (nAMD) receiving vascular endothelial growth factor (VEGF) inhibitors in daily pra...

Chargement des enrichissements...